Xanthon Inc.
This article was originally published in Start Up
Executive Summary
Molecular Diagnostics. Xanthon claims it is developing a platform technology that will allow target squences of DNA or RNA to be detected with far less handling than PCR now requires. The technology takes advantage of the electrochemical properties of DNA. Xanthon attaches a membrane to an electrode and probes to the membrane. If a target sequence is present in the sample exposed to the membrane, it will bind, or hybridize there.